Adenovirus-vectored vaccines

被引：5

作者：

Chawla, Tanu ^{[1
]}

Khanna, Navin ^{[1
]}

Swaminathan, Sathyamangalam ^{[1
]}

机构：

[1] Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi 110067, India

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2008年 / 18卷 / 03期

关键词：

adenovirus; AIDS; dengue; malaria; prior immunity; tuberculosis; vaccines;

D O I：

10.1517/13543776.18.3.293

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Background: Engineered adenoviruses are being increasingly explored as immunoprophylactic or immunotherapeutic vaccine vectors. Encouraging data from preclinical studies using human adenovirus vectors carrying different antigen genes have resulted in many currently ongoing clinical trials. Objective: The article seeks to review the current status of the use of adenoviruses as vaccine vectors. Methods: This review is based on the patent literature since 2000 pertaining to the development of adenovirus vaccine vectors for infectious and non-infectious diseases. Conclusion: Human adenovirus-vectored vaccines have important limitations that stem from their immunogenicity and restrict their utility. This has spurred intensive efforts to find alternative adenovirus vectors and strategies, each with its own advantages and shortcomings.

引用

页码：293 / 307

页数：15

共 123 条

[1] A simple method for the rapid generation of recombinant adenovirus vectors [J].

Anderson, RD ;

Haskell, RE ;

Xia, H ;

Roessler, BJ ;

Davidson, BL .

GENE THERAPY, 2000, 7 (12) :1034-1038

[2] Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus [J].

Arribillaga, L ;

de Cerio, ALD ;

Sarobe, P ;

Casares, N ;

Gorraiz, M ;

Vales, A ;

Bruna-Romero, O ;

Borrás-Cuesta, F ;

Paranhos-Baccala, G ;

Prieto, J ;

Ruiz, J ;

Lasarte, JJ .

VACCINE, 2002, 21 (3-4) :202-210

[3] Development of nonhuman adenoviruses as vaccine vectors [J].

Bangari, DS ;

Mittal, SK .

VACCINE, 2006, 24 (07) :849-862

[4] Rational design of gene-based vaccines [J].

Barouch, DH .

JOURNAL OF PATHOLOGY, 2006, 208 (02) :283-289

[5] Adenovirus vector-based vaccines for human immunodeficiency virus type 1 [J].

Barouch, DH ;

Nabel, GJ .

HUMAN GENE THERAPY, 2005, 16 (02) :149-156

[6] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[7] Adenovirus vectors for gene delivery [J].

Benihoud, K ;

Yeh, P ;

Perricaudet, M .

CURRENT OPINION IN BIOTECHNOLOGY, 1999, 10 (05) :440-447

[8]

BOUT A, 2004, EP1054064

[9]

CANC CTR S YATSEN U, 2005, Patent No. 2005117961

[10] A transgenic mouse with β-Galactosidase as a fetal liver self-antigen for immunotherapy studies [J].

Cany, Jeannette ;

Avril, Audrey ;

Pichard, Virginie ;

Aubert, Dominique ;

Ferry, Nicolas ;

Conchon, Sophie .

JOURNAL OF HEPATOLOGY, 2007, 47 (03) :396-403

← 1 2 3 4 5 6 7 8 9 10 →